Presentations Highlight the Benefits of Enzymatic Debridement

YAVNE, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that seven presentations highlighting the positive clinical results from using NexoBrid^® as an enzymatic debridement for severe burns and EscharEx for the debridement of chronic wounds will be presented during the Symposium on Advanced Wound Care Spring/Wound Healing Society Meeting (SAWC Spring), taking place April 5-9, 2017 in San Diego, California. 

“We are delighted with the depth and breadth of data to be presented at this year’s SAWC Spring in support of the effectiveness of EscharEx and NexoBrid in wound management and burn care, respectively.  We are pleased to have the positive data from our EscharEx Phase 2 clinical trial presented as it demonstrates the important role this product can play in the treatment of chronic wounds. Debridement is a critical first step to facilitate wound management and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. It is thought that EscharEx could allow more patients to benefit from advanced wound healing and skin substitute products, which generally are not applied on wounds covered with eschar.  We believe EscharEx can fill the long-standing unmet medical need for an effective and rapid nonsurgical debridement treatment for chronic wounds,” said Gal Cohen, President and Chief Executive Officer of MediWound.

“The SAWC Spring meeting is a particularly good program as it brings together the entire interdisciplinary wound care team to learn more about advances in the field that will facilitate improved patient outcomes.  We look forward to sharing our compelling data with these clinicians and to expanding the awareness of our proteolytic enzyme technologies as effective debridement treatments in severe burns and chronic wounds,” added Mr. Cohen. 

The following data highlighting NexoBrid and EscharEx will be presented during the SAWC Spring meeting: 

About SAWC Spring/Wound Healing Society Meeting

The Symposium on Advanced Wound Care/Wound Healing Society Meeting is the nation’s largest and most well-respected interdisciplinary wound care program within the clinical field. The Symposium on Advanced Wound Care Spring | Wound Healing Society meeting (SAWC Spring | WHS) serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists and dietitians — with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research findings.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid^®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid^® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.

MediWound's second innovative product, EscharEx^® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx^® contains the same proteolytic enzyme technology as NexoBrid^®, and benefits from the wealth of existing development data on NexoBrid^®.  In two Phase 2 studies, EscharEx^® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications.   For more information, please visit www.mediwound.com. 

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2016 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.